Congenital Myasthenic Syndromes

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, morphologic, and molecular genetic studies have paved the way for defining phenotypic features of the different syndromes, identifying disease genes and proteins, and recommending appropriate therapy. Disease proteins reside in the nerve terminal, the synaptic basal lamina, or the postsynaptic region of the neuromuscular junction, or are distributed in many tissues including the junction. Those identified to date include choline acetyltransferase, the endplate species of acetylcholinesterase β2-laminin, each subunit of the acetylcholine receptor, rapsyn, plectin, Nav1.4, MuSK, agrin, Dok-7, GFPT1, DPAGT1, ALG2, and ALG14. Analyses of properties of expressed mutant proteins contribute to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

Original languageEnglish (US)
Title of host publicationNeuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach
PublisherElsevier Inc.
Pages456-481
Number of pages26
ISBN (Print)9780124171275, 9780124170445
DOIs
StatePublished - Dec 3 2014

Fingerprint

Congenital Myasthenic Syndromes
Plectin
Agrin
Choline O-Acetyltransferase
Neuromuscular Junction
Presynaptic Terminals
Cholinergic Receptors
Laminin
Mutant Proteins
Acetylcholinesterase
Basement Membrane
Molecular Biology
Proteins
Safety
Therapeutics
Genes

Keywords

  • Acetylcholine receptor
  • Agrin
  • ALG14
  • ALG2
  • Choline acetyltransferase
  • ColQ
  • Congenital myasthenic syndrome
  • DAPGT1
  • Dok-7
  • EMG
  • Fetal akinesia syndrome
  • GFPT1
  • MuSK
  • Neuromuscular junction
  • Plectin
  • Rapsyn
  • β2-laminin

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Engel, A. G. (2014). Congenital Myasthenic Syndromes. In Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach (pp. 456-481). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-417044-5.00026-3

Congenital Myasthenic Syndromes. / Engel, Andrew G.

Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Elsevier Inc., 2014. p. 456-481.

Research output: Chapter in Book/Report/Conference proceedingChapter

Engel, AG 2014, Congenital Myasthenic Syndromes. in Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Elsevier Inc., pp. 456-481. https://doi.org/10.1016/B978-0-12-417044-5.00026-3
Engel AG. Congenital Myasthenic Syndromes. In Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Elsevier Inc. 2014. p. 456-481 https://doi.org/10.1016/B978-0-12-417044-5.00026-3
Engel, Andrew G. / Congenital Myasthenic Syndromes. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Elsevier Inc., 2014. pp. 456-481
@inbook{230d5df53aa941e7b7c2fca496eeecf5,
title = "Congenital Myasthenic Syndromes",
abstract = "Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, morphologic, and molecular genetic studies have paved the way for defining phenotypic features of the different syndromes, identifying disease genes and proteins, and recommending appropriate therapy. Disease proteins reside in the nerve terminal, the synaptic basal lamina, or the postsynaptic region of the neuromuscular junction, or are distributed in many tissues including the junction. Those identified to date include choline acetyltransferase, the endplate species of acetylcholinesterase β2-laminin, each subunit of the acetylcholine receptor, rapsyn, plectin, Nav1.4, MuSK, agrin, Dok-7, GFPT1, DPAGT1, ALG2, and ALG14. Analyses of properties of expressed mutant proteins contribute to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.",
keywords = "Acetylcholine receptor, Agrin, ALG14, ALG2, Choline acetyltransferase, ColQ, Congenital myasthenic syndrome, DAPGT1, Dok-7, EMG, Fetal akinesia syndrome, GFPT1, MuSK, Neuromuscular junction, Plectin, Rapsyn, β2-laminin",
author = "Engel, {Andrew G}",
year = "2014",
month = "12",
day = "3",
doi = "10.1016/B978-0-12-417044-5.00026-3",
language = "English (US)",
isbn = "9780124171275",
pages = "456--481",
booktitle = "Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Congenital Myasthenic Syndromes

AU - Engel, Andrew G

PY - 2014/12/3

Y1 - 2014/12/3

N2 - Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, morphologic, and molecular genetic studies have paved the way for defining phenotypic features of the different syndromes, identifying disease genes and proteins, and recommending appropriate therapy. Disease proteins reside in the nerve terminal, the synaptic basal lamina, or the postsynaptic region of the neuromuscular junction, or are distributed in many tissues including the junction. Those identified to date include choline acetyltransferase, the endplate species of acetylcholinesterase β2-laminin, each subunit of the acetylcholine receptor, rapsyn, plectin, Nav1.4, MuSK, agrin, Dok-7, GFPT1, DPAGT1, ALG2, and ALG14. Analyses of properties of expressed mutant proteins contribute to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

AB - Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, morphologic, and molecular genetic studies have paved the way for defining phenotypic features of the different syndromes, identifying disease genes and proteins, and recommending appropriate therapy. Disease proteins reside in the nerve terminal, the synaptic basal lamina, or the postsynaptic region of the neuromuscular junction, or are distributed in many tissues including the junction. Those identified to date include choline acetyltransferase, the endplate species of acetylcholinesterase β2-laminin, each subunit of the acetylcholine receptor, rapsyn, plectin, Nav1.4, MuSK, agrin, Dok-7, GFPT1, DPAGT1, ALG2, and ALG14. Analyses of properties of expressed mutant proteins contribute to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.

KW - Acetylcholine receptor

KW - Agrin

KW - ALG14

KW - ALG2

KW - Choline acetyltransferase

KW - ColQ

KW - Congenital myasthenic syndrome

KW - DAPGT1

KW - Dok-7

KW - EMG

KW - Fetal akinesia syndrome

KW - GFPT1

KW - MuSK

KW - Neuromuscular junction

KW - Plectin

KW - Rapsyn

KW - β2-laminin

UR - http://www.scopus.com/inward/record.url?scp=84944561984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944561984&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-417044-5.00026-3

DO - 10.1016/B978-0-12-417044-5.00026-3

M3 - Chapter

SN - 9780124171275

SN - 9780124170445

SP - 456

EP - 481

BT - Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach

PB - Elsevier Inc.

ER -